Astera, you are right there. Spicer69 getting a bit carried...

Astera, you are right there. Spicer69 getting a bit carried away? lol. But the effect Bio A has shown is still remarkable against H. pylori strains. Trial results are expected soon.

That said I have a feeling that Spicer69 was thinking of Methicillin Resistant Staphylococcus. Quote: MRSA is a growing public health concern, and is cited as the leading cause of Hospital Acquired Infections (HAI's). According to the U.S. Centers for Disease Control and Prevention (CDC), HAI's number over 2 million annually, and that more than 100,000 hospital patients die each year as a result of contracting an infection while being treated for another condition. According to U.S. Congressional Record (H.R. Bill 1174), these HAI's contribute to over $50 billion in annual medical costs. MRSA infection rates have increased every year since 1970
MRSA is a bacterium that is resistant to antibiotics including methicillin, oxacillin, penicillin and amoxicillin affecting those with weakened immune systems such as hospital patients and nursing home residents. When MRSA enters the body through the skin it can cause serious skin infections, and if it enters the bloodstream or lungs, it can cause critical blood infections, pneumonia and even death.

Bioeffective A also proved effective
against Methicillin Resistant Staphylococcus strains (including MRSE and MRSA which are responsible for a large proportion of hospital infections).

And with relation to Helicobacter Pylori strains:
Quote:
The anti-microbial trial was designed to understand the ability of Bioeffective A to inhibit a
range of different bacteria and fungi, and compare its activity to that of a series of well known
effective antibiotics and antifungals, together with well-established natural anti-microbials. It
was also designed to establish whether the broad activity spectrum of Bioeffective A might
provide a means through which some of the shortcomings associated with conventional
antibiotic treatments could be overcome. These include:
* The toxicity of synthetic antibiotics which means that they can only be used in limited
doses without creating significant side effects
* The fact that effective natural anti-microbials such as Tea Tree Oil generally only work in
topical applications
* The fact that synthetic antibiotics are designed mainly for internal use – even though
some infections require topical as well as internal treatment
* The frequency with which treatment with synthetic antibiotics fail, meaning that a number
of different antibiotics are sometimes tried before an infection is brought under control
* The fact that synthetic antibiotics tend to only be effective against selective strains of
bacteria, but many infections involve a range of different bacteria
* The development of antibiotic resistant strains
* The fact that synthetic antibiotics can destroy microflora, removing natural constraints on
the activation and uncontrolled growth of Candida which is often difficult to manage

The first of these trials to be completed is a wide ranging anti-microbial study. The other trials
involve calibrating the anti-oxidant properties of Bioeffective A, and establishing its ability to
inhibit the growth and reproduction of Helicobacter Pylori (the bacterium associated with
ulcers of the gastrointestinal system).


Hope that clears it up a bit.

Cheers Greg